Skip to main content
Signal8

Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio

$GILDPress releaseMay 21, 2026, 9:30 AM ETRead the release

Gilead Sciences has completed its acquisition of Tubulis GmbH, a German clinical-stage biotech specializing in next-generation antibody-drug conjugates (ADCs). The deal was finalized for $3.15 billion in upfront cash on a cash-free, debt-free basis, with up to $1.85 billion in additional contingent milestone payments.

Key figures

Deal Value Usd
3150000000
Milestone payments
1850000000
Total potential value
5000000000

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.